Company & Sponsor Intelligence

University of Cincinnati

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials7

Recruiting0

Completed6

Countries1

Therapeutic footprint

adhdepilepsyother_psychiatryparkinsonsstroke

Indexed studies

NCT02478788Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder
adhd · United StatesPHASE4

NCT00477802Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease
parkinsons · United StatesPHASE4

NCT01733394Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)
epilepsy · United StatesPHASE4

NCT02470780Treating Bacterial Overgrowth in Parkinson's Disease
parkinsons · United StatesPHASE2, PHASE3

NCT04553198Quantifying the Role of Sensory Systems Processing in Post-Stroke Walking Recovery
stroke · United StatesNA

NCT05273398Effects of Diazepam on RNS Detections
epilepsy · United StatesPHASE4

NCT01641159Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence
other_psychiatry · United StatesPHASE2

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →